Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 trial of CK-0804 in JAK ihnibitor resistant/ suboptimal myelofibrosis

Next Previous
Trial Profile

A phase 2 trial of CK-0804 in JAK ihnibitor resistant/ suboptimal myelofibrosis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CK 0804 (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use

Most Recent Events

  • 06 Jan 2026 According to a Cellenkos media release,company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational product, CK0804, for treatment of myelofibrosis.
  • 20 Dec 2025 New trial record
  • 10 Dec 2025 According to a Cellenkos media release, the company will initiate phase 2 trial of CK0804 in JAK ihnibitor resistant/ suboptimal myelofibrosis, as the responses in thrombocytopenic patients (failed or had suboptimal benefit from prior JAK inhibitor therapy) are encouraging and pave way for phase 2 trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top